JUST IN: Limited-Time Access to Full Transcript of Our Urgent Broadcast on India's Revival
Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 2.0 |
No. of shares | m | 126.20 |
% ch week | % | 3.9 |
% ch 1-mth | % | 11.7 |
% ch 12-mth | % | 41.1 |
52 week H/L | Rs | 2,455.6/1,442.7 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
IPCA LABS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 899 | 888 | 643 | 695 | 1,042 | |
Low | Rs | 591 | 629 | 503 | 400 | 590 | |
Sales per share (Unadj.) | Rs | 249.2 | 230.3 | 254.5 | 260.2 | 298.6 | |
Earnings per share (Unadj.) | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
Diluted earnings per share | Rs | 20.1 | 7.6 | 15.4 | 19.0 | 35.0 | |
Cash flow per share (Unadj.) | Rs | 34.4 | 20.6 | 29.1 | 33.1 | 49.4 | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | 1.00 | 1.00 | 3.00 | |
Adj. dividends per share | Rs | 1.00 | 0.00 | 1.00 | 1.00 | 3.00 | |
Dividend yield (eoy) | % | 0.1 | 0 | 0.2 | 0.2 | 0.4 | |
Book value per share (Unadj.) | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.1 | |
Adj. book value per share | Rs | 174.1 | 179.0 | 194.6 | 213.0 | 247.4 | |
Shares outstanding (eoy) | m | 126.20 | 126.20 | 126.20 | 126.20 | 126.35 | |
Bonus/Rights/Conversions | - | - | - | - | ESOS | ||
Price / Sales ratio | x | 3.0 | 3.3 | 2.3 | 2.1 | 2.7 | |
Avg P/E ratio | x | 37.0 | 99.5 | 37.2 | 28.9 | 23.3 | |
P/CF ratio (eoy) | x | 21.7 | 36.9 | 19.7 | 16.6 | 16.5 | |
Price / Book Value ratio | x | 4.3 | 4.2 | 2.9 | 2.6 | 3.3 | |
Dividend payout | % | 5.0 | 0 | 6.5 | 5.3 | 8.6 | |
Avg Mkt Cap | Rs m | 94,057 | 95,723 | 72,300 | 69,120 | 103,108 | |
No. of employees | `000 | 13.0 | 13.1 | 13.3 | 13.3 | 13.4 | |
Total wages/salary | Rs m | 5,651 | 6,256 | 6,960 | 7,359 | 7,874 | |
Avg. sales/employee | Rs Th | 2,416.4 | 2,213.3 | 2,414.6 | 2,477.4 | 2,807.0 | |
Avg. wages/employee | Rs Th | 434.3 | 476.4 | 523.2 | 555.2 | 585.8 | |
Avg. net profit/employee | Rs Th | 195.4 | 73.3 | 146.2 | 180.6 | 329.0 |
IPCA LABS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 31,444 | 29,065 | 32,122 | 32,836 | 37,732 | |
Other income | Rs m | 327 | 222 | 210 | 418 | 577 | |
Total revenues | Rs m | 31,771 | 29,287 | 32,332 | 33,254 | 38,309 | |
Gross profit | Rs m | 5,363 | 2,896 | 4,381 | 4,505 | 6,901 | |
Depreciation | Rs m | 1,796 | 1,633 | 1,730 | 1,777 | 1,824 | |
Interest | Rs m | 284 | 319 | 241 | 240 | 189 | |
Profit before tax | Rs m | 3,611 | 1,166 | 2,621 | 2,905 | 5,465 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | -49 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,019 | 204 | 675 | 511 | 1,042 | |
Profit after tax | Rs m | 2,542 | 962 | 1,945 | 2,394 | 4,422 | |
Gross profit margin | % | 17.1 | 10.0 | 13.6 | 13.7 | 18.3 | |
Effective tax rate | % | 28.2 | 17.5 | 25.8 | 17.6 | 19.1 | |
Net profit margin | % | 8.1 | 3.3 | 6.1 | 7.3 | 11.7 |
IPCA LABS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 19,348 | 16,219 | 17,418 | 19,455 | 23,778 | |
Current liabilities | Rs m | 12,517 | 9,700 | 9,559 | 10,076 | 10,975 | |
Net working cap to sales | % | 21.7 | 22.4 | 24.5 | 28.6 | 33.9 | |
Current ratio | x | 1.5 | 1.7 | 1.8 | 1.9 | 2.2 | |
Inventory Days | Days | 107 | 105 | 100 | 98 | 104 | |
Debtors Days | Days | 73 | 56 | 57 | 67 | 66 | |
Net fixed assets | Rs m | 20,540 | 21,429 | 20,779 | 20,435 | 20,368 | |
Share capital | Rs m | 252 | 252 | 252 | 252 | 253 | |
"Free" reserves | Rs m | 21,564 | 22,578 | 24,300 | 26,633 | 30,971 | |
Net worth | Rs m | 21,965 | 22,592 | 24,553 | 26,886 | 31,224 | |
Long term debt | Rs m | 4,987 | 4,843 | 3,517 | 2,340 | 1,409 | |
Total assets | Rs m | 41,248 | 38,917 | 39,595 | 41,173 | 45,507 | |
Interest coverage | x | 13.7 | 4.7 | 11.9 | 13.1 | 30.0 | |
Debt to equity ratio | x | 0.2 | 0.2 | 0.1 | 0.1 | 0 | |
Sales to assets ratio | x | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | |
Return on assets | % | 6.9 | 3.3 | 5.5 | 6.4 | 10.1 | |
Return on equity | % | 11.6 | 4.3 | 7.9 | 8.9 | 14.2 | |
Return on capital | % | 14.3 | 5.4 | 10.2 | 10.8 | 17.3 | |
Exports to sales | % | 52.9 | 49.2 | 48.6 | 47.6 | 45.9 | |
Imports to sales | % | 16.7 | 15.3 | 14.2 | 14.9 | 16.6 | |
Exports (fob) | Rs m | 16,624 | 14,299 | 15,617 | 15,642 | 17,308 | |
Imports (cif) | Rs m | 5,247 | 4,445 | 4,571 | 4,884 | 6,266 | |
Fx inflow | Rs m | 16,749 | 14,299 | 15,617 | 15,642 | 17,308 | |
Fx outflow | Rs m | 6,956 | 5,822 | 4,571 | 4,884 | 6,266 | |
Net fx | Rs m | 9,793 | 8,477 | 11,046 | 10,759 | 11,042 |
IPCA LABS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 4,682 | 7,087 | 2,819 | 3,411 | 4,923 | |
From Investments | Rs m | -6,893 | -2,183 | -1,488 | -1,354 | -1,563 | |
From Financial Activity | Rs m | 2,505 | -4,615 | -1,591 | -1,304 | -1,832 | |
Net Cashflow | Rs m | 294 | 288 | -260 | 753 | 1,528 |
Share Holding
|
Company Information
|
CHM: Premchand Godha (MD) | COMP SEC: Harish P. Kamath (VP - Legal) | YEAR OF INC: 1949 | BSE CODE: 524494 | FV (Rs): 2 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: WYETH TTK HEALTHCARE PANACEA BIOTECH ALKEM LABORATORIES TORRENT PHARMA
Compare IPCA LABS With: WYETH TTK HEALTHCARE PANACEA BIOTECH ALKEM LABORATORIES TORRENT PHARMA
Compare IPCA LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More